Online inquiry

IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12170MR)

This product GTTS-WQ12170MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12170MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ995MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ7454MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ4860MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ13178MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ652MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ6188MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ15267MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ6204MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW